In vivo mutagenicity of vinyl carbamate and ethyl carbamate in lung and small intestine of F1 (Big Blue® × A/J) transgenic mice

International Journal of Cancer

Volumn 120, Issue 7, 2007, Pages 1426-1433

  Hernandez, Lya G ^a   Forkert, Poh Gek ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

cII in Big Blue mice; Ethyl carbamate; Lung; Mutant frequency; Vinyl carbamate

Indexed keywords

ALCOHOL; CARBAMIC ACID; CARBAMIC ACID VINYL ESTER; DNA; MUTAGENIC AGENT; UNCLASSIFIED DRUG; URETHAN; VINYL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; FERMENTATION; FOOD INTAKE; GENE MUTATION; LIVER; LUNG CANCER; LUNG CARCINOGENESIS; MALE; MOUSE; MOUSE STRAIN; MUTAGENICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMALL INTESTINE CANCER; TRANSGENIC MOUSE;

ANIMALS; CARCINOGENS; COLON; FEMALE; INTESTINE, SMALL; LUNG; MICE; MICE, INBRED A; MICE, TRANSGENIC; MUTATION; POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; URETHANE; VIRAL PROTEINS;

EID: 33847629219     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22502     Document Type: Article

References (44)

1. Battaglia R, Conacher HB, Page BD. Ethyl carbamate (urethane) in alcoholic beverages and foods: a review. Food Addit Contam 1990;7:477-96.
2. Zimmerli B, Schlatter J. Ethyl carbamate: analytical methodology, occurrence, formation, biological activity, and risk assessment. Mutat Res 1991;259:325-50.
3. Miller JA. The need for epidemiological studies of the medical exposures of Japanese patients to the carcinogen ethyl carbamate (urethane) from 1950 to 1975. Jpn J Cancer Res 1991;82:1323-4.
4. Nomura T. Urethane (ethyl carbamate) as a co-solvent of drugs commonly used parenterally in humans. Cancer Res 1975;35:2895-9.
5. Ough CS. Ethyl carbamate in fermented beverages and foods. 1. Naturally occurring ethyl carbamate. J Agric Food Chem 1976;24:323-8.
6. International Agency for Research on Cancer. IARC monographs on the evaluation risk of chemicals to man, vol. 7. Lyon, France: IARC, 1974. 111-40.
7. Nettleship A, Henshaw PS, Meyer HL. Induction of pulmonary tumors in mice with ethyl carbamate (urethane). J Natl Cancer Inst 1943;4:309-19.
8. Salaman MH, Roe FJ. Incomplete carcinogens: ethyl carbamate (urethane) as an initiator of skin tumour formation in the mouse. Br J Cancer 1953;7:472-81.
9. Tannenbaum A. Contributions of urethane studies to the understanding of carcinogenesis. Natl Cancer Inst Monogr 1964;14:341-56.
10. Mirvish SS. The carcinogenic action and metabolism of urethane and N-hydroxyurethane. Adv Cancer Res 1968;11:1-42.
11. Shimkin MB, Stoner GD. Lung tumors in mice: application to carcinogenesis bioassay. Adv Cancer Res 1975;21:1-58.
12. Dahl GA, Miller JA, Miller EC. Vinyl carbamate as a promutagen and a more carcinogenic analog of ethyl carbamate. Cancer Res 1978;38:3793-804.
13. Dahl GA, Miller JA, Miller EC. Comparative carcinogenicities and mutagenicities of vinyl carbamate, ethyl carbamate, and ethyl N-hydroxycarbamate. Cancer Res 1980;40:1194-203.
14. 14C]ethyl carbamate (urethan). Carcinogenesis 1982;3:539-46.
15. Forkert PG, Lee RP. Metabolism of ethyl carbamate by pulmonary cytochrome P450 and carboxylesterase isoenzymes: involvement of CYP2E1 and hydrolase A. Toxicol Appl Pharmacol 1997;146:245-54.
16. Forkert PG, Lee RP, Reid K. Involvement of CYP2E1 and carboxylesterase enzymes in vinyl carbamate metabolism in human lung microsomes. Drug Metab Dispos 2001;29:258-63.
17. Leithauser MT, Liem A, Stewart BC, Miller EC, Miller JA. 1,N6-ethenoadenosine formation, mutagenicity, and murine tumor as indicators of the generation of an electrophilic epoxide metabolite of the closely related carcinogens ethyl carbamate (urethane) and vinyl carbamate. Carcinogenesis 1990;11:463-73.
18. Park KK, Surh YJ, Stewart BC, Miller JA. Synthesis and properties of vinyl carbamate epoxide, a possible ultimate electrophilic and carcinogenic metabolite of vinyl carbamate and ethyl carbamate. Biochem Biophys Res Commun 1990;169:1094-8.
19. Park KK, Liem A, Stewart BC, Miller JA. Vinyl carbamate epoxide, a major strong electrophilic, mutagenic, and carcinogenic metabolite of vinyl carbamate and ethyl carbamate (urethane). Carcinogenesis 1993;14:441-50.
20. Fernando RC, Nair J, Barbin A, Miller JA, Bartsch H. Detection of 1,N6-ethenodeoxyadenosine and 3,N4-ethenodeoxycytidine by immunoaffinity/32P-postlabelling in liver and lung DNA of mice treated with ethyl carbamate (urethane) or its metabolites. Carcinogenesis 1996;17:1711-18.
21. - transgenic mice. Mutagenesis 1998;13:133-7.
22. Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Sorge JA, Putman DL, Short JM. Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc Natl Acad Sci USA 1991;88:7958-62.
23. Jakubczak JL, Merlino G, French JE, Muller WJ, Paul B, Adhya S, Garges S. Analysis of genetic instability during mammary tumor progression using a novel-based assay for in vivo mutations in the bacteriophage λ transgene target. Proc Natl Acad Sci USA 1996;93:9073-8.
24. Swiger RR, Cosentino L, Shima N, Bielas JH, Cruz-Munoz W, Heddle JA. The cII locus in. Muta Mouse. Environ Mol Mutagen 1999;34:201-4.
25. Malkinson AM. Genetic studies on lung tumor susceptibility and histogenesis in mice. Environ Health Perspect 1991;93:149-59.
26. Titis AP, Forkert PG. Strain-related differences in bioactivation of vinyl carbamate and formation of DNA adducts in lungs of A/J, CD-1, and C57BL/6 mice. Toxicol Sci 2001;59:82-91.
27. Heddle JA. Mutant manifestation: the time factor in somatic mutagenesis. Mutagenesis 1999;14:1-3.
28. Cosentino L, Heddle JA. A test for neutrality of mutations of the lacZ transgene. Environ Mol Mutagen 1996;28:313-16.
29. Douglas GR, Jiao J, Gingerich JD, Soper LM, Gossen JA. Temporal and molecular characteristics of lacZ mutations in somatic transgenic mice. Environ Mol Mutagen 1996;28:317-24.
30. Sun B, Heddle JA. The relationship between mutant frequency and time in vivo: simple predictions for any tissue, cell type, mutagen. Mutat Res 1999;425:179-83.
31. Tao KS, Urlando C, Heddle JA. Comparison of somatic mutations in transgenic versus host locus. Proc Natl Acad Sci USA 1993;90:10681-5.
32. Thybaud V, Dean S, Nohmi T, de Boer J, Douglas GR, Glickman B, Gorelick NJ, Heddle JA, Heflich RH, Lambert I, Martus HJ, Mirsalis JC, et al. In vivo transgenic mutation assays. Mutat Res 2003;540:141-4.
33. Cariello NF, Piegorsch WW, Adams WT, Skopek TR. Computer program for the analysis of mutational spectra: application to p53 mutations. Carcinogenesis 1994;15:2281-5.
34. Gossen JA, de Leeuw WJ, Tan CH, Zwarthoff EC, Berends F, Lohman PH, Knook DL, Vijg J. Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo. Proc Natl Acad Sci USA 1989;86:7971-5.
35. Harbach PR, Zimmer DM, Filipunas AL, Mattes WB, Aaron CS. Spontaneous mutation spectrum at the lambda cII locus in liver, lung, and spleen tissue of Big Blue® transgenic mice. Environ Mol Mutagen 1999;33:132-43.
36. Rideout WM, III, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1999;249:1288-90.
37. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001;477:7-21.
38. Forkert PG, Lee PL. Metabolism of ethyl carbamate by pulmonary cytochrome P450 and carboxylesterase isozymes: involvement of CYP2E1 and hydrolase A. Toxicol Appl Pharmacol 1997;146:245-54.
39. Barbin A. Etheno-adduct-forming chemicals: from mutagenicity testing to tumor mutation spectra. Mutat Res 2000;462:55-69.
40. Pandya GA, Moriya M. 1,N6-ethenodeoxyadenosine, a DNA adduct highly mutagenic in mammalian cells. Biochemistry 1996;35:11487-92.
41. Moriya M, Zhang W, Johnson F, Grollman AP. Mutagenic potency of exocyclic DNA adducts: marked differences between Escherichia coli and simian kidney cells. Proc Natl Acad Sci USA 1994;91:11899-903.
42. Bartsch H, Barbin A, Marion MJ, Nair J, Guichard Y. Formation, detection, and role in crcinogenesis of ethenobases in DNA. Drug Metab Rev 1994;26:349-71.
43. Heddle JA, Martus HJ, Douglas GR. Treatment and sampling protocols for transgenic mutation assays. Environ Mol Mutagen 2003;41:1-6.
44. 1 mice. Food Chem Toxicol 2005;43:1-19.